Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Non-Current Assets (2023 - 2026)

Contineum Therapeutics' Non-Current Assets history spans 4 years, with the latest figure at $8.4 million for Q1 2026.

  • Quarterly Non-Current Assets rose 36.79% to $8.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $29.1 million through Mar 2026, up 100.34% year-over-year, with the annual reading at $8.7 million for FY2025, 35.08% up from the prior year.
  • Non-Current Assets came in at $8.4 million for Q1 2026, down from $8.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $8.7 million in Q4 2025 to a low of $891000.0 in Q3 2024.
  • The 4-year median for Non-Current Assets is $6.0 million (2025), against an average of $5.0 million.
  • The largest YoY upside for Non-Current Assets was 564.42% in 2025 against a maximum downside of 35.08% in 2025.
  • Contineum Therapeutics' Non-Current Assets stood at $2.7 million in 2023, then soared by 141.01% to $6.5 million in 2024, then skyrocketed by 35.08% to $8.7 million in 2025, then dropped by 3.9% to $8.4 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Non-Current Assets are $8.4 million (Q1 2026), $8.7 million (Q4 2025), and $5.9 million (Q3 2025).